Retatrutide at the 12 mg dose produced nausea in 38-43% of Phase 3 trial participants
Gut healing and gastrointestinal repair benefit from direct peptide contact with digestive tissues
10.1016/j.jep.2022.115333 78 LiangZ.PiD.ZhenJ.YanH.ZhengC.Liang ChenJ.et al (2024)
What the FDA will review (and when) According to the FDA Law Blog breakdown, the FDA has scheduled the Pharmacy Compounding Advisory Committee (PCAC) to review peptides for possible inclusion on the Section 503A bulks list on two timelines: PCAC meeting: July 2324, 2026 July 23: BPC-157, KPV, TB-500, MOTs-C (FDA Law Blog) July 24: Emideltide (DSIP), Semax, Epithalon (FDA Law Blog) Second PCAC meeting: before the end of February 2027 GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, PEG-MGF (FDA Law Blog) Well update this post as the FDA releases briefing packets, conflict-of-interest disclosures, and voting questions closer to the meeting
Nutrients 15:3258
Features a lightweight, rapidly absorbing formula that prepares the skin for subsequent treatment steps without leaving a sticky finish
